Application Detail

Description of Medical Service

Testing of prostate tumour tissue (somatic) and germline to detect BRCA1/2 (BReast CAncer) gene mutations in men with metastatic castration-resistant prostate cancer, to determine their eligibility for treatment with PBS-listed Talazoparib.

Description of Medical Condition

Prostate cancer is termed ‘castrate resistant’ when the disease progresses despite continuous androgen deprivation therapy. This application concerns the metastatic disease stage of prostate cancer, which constitutes a small proportion of the overall disease, and additionally targeting a subgroup of patients with genetic mutations in their homologous recombination repair genes.

Reason for Application

Amendment to MBS item

Medical Service Type

Investigative technology

Previous Application Number/s

Not Applicable

Associated Documentation

Application Summary and PICO Set

Application Summary (PDF 399 KB)
Application Summary (Word 36 KB)

PICO Set (PDF 1342 KB)
PICO Set (Word 497 KB)

Consultation Survey

Consultation Survey (PDF 662 KB)
Consultation Survey (Word 27 KB)

MSAC Consultation
MSAC consultation input closed Friday, 16 February 2024.

For further information please refer to PASC, ESC, MSAC Key Dates
For further information on the consultation process please refer to MSAC Consultation Process

PICO Confirmation

-

Assessment Report

-

Public Summary Document

Public Summary Document (PDF 282 KB)
Public Summary Document (Word 105 KB)

Meetings for this Application

PASC

Expedited - Bypassing PASC

ESC

Expedited - Bypassing ESC

MSAC

4-5 April 2024